Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial

[1]  上村 直実.  ガイドライン解説 ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2010 .

[2]  S. Nakajima,et al.  Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years , 2010, Journal of gastroenterology and hepatology.

[3]  K. Sugano,et al.  Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition , 2010, Helicobacter.

[4]  N. Talley.  Continuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding: A Randomized Trial , 2010 .

[5]  B. Wong,et al.  Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. , 2010, Gastroenterology.

[6]  V. Bezlyak,et al.  Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[7]  M. Hara,et al.  Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy , 2009, Journal of Gastroenterology.

[8]  M. Asaka,et al.  Investigation of Gastric and Duodenal Mucosal Defects Caused by Low-dose Aspirin in Patients With Ischemic Heart Disease , 2009, Journal of clinical gastroenterology.

[9]  H. Imamura,et al.  Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin , 2009, Journal of Gastroenterology.

[10]  E. Antman,et al.  ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2008, The American Journal of Gastroenterology.

[11]  C. Hawkey,et al.  Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin , 2008, The American Journal of Gastroenterology.

[12]  M. Asaka,et al.  Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial , 2008, The Lancet.

[13]  K. Fujimori,et al.  A clinical study of Japanese patients with ulcer induced by low‐dose aspirin and other non‐steroidal anti‐inflammatory drugs , 2005, Alimentary pharmacology & therapeutics.

[14]  K. Chu,et al.  Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. , 2002, The New England journal of medicine.

[15]  K. Sugano,et al.  Guidelines in the Management of Helicobacter pylori Infection in Japan , 2001, Helicobacter.

[16]  F. Chan,et al.  Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. , 2001, The New England journal of medicine.

[17]  T. Koike,et al.  Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylorieradication , 2000, Gut.

[18]  Y. Shiratori,et al.  Major virulence factors, VacA and CagA, are commonly positive inHelicobacter pylori isolates in Japan , 1998, Gut.

[19]  D. T. Lyon.  Efficacy and safety of famotidine in the management of benign gastric ulcers. , 1986, The American journal of medicine.

[20]  A. Ishimori,et al.  Therapeutic effect of pirenzepine dihydrochloride on gastric ulcer evaluated by a double-blind controlled clinical study. Phase III study. , 1982, Arzneimittel-Forschung.

[21]  R. Nelson,et al.  A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. , 1981, The American journal of gastroenterology.